Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 59

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 59
---
     | 4,718,862 |                                                                                                                                                |     |            |     |

* The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant.

^ Amount of equity award adjustments may differ from amount reported in the table above due to rounding.

(4) For the relevant fiscal year, represents the cumulative TSR of our common stock and the NASDAQ Biotechnology Index at the end of each fiscal year. In each case, assume an initial investment of $100 on December 31, 2021.

(5) The dollar amounts reported represent the amount of Net Loss reflected in the Company’s audited financial statements for the applicable year.

(6) As required by Item 402(v) of Regulation S-K, we have determined that net product salesis the Company-Selected Measure, the calculation of which is described in our Annual Report. Net product sales may not have been the most important financial performance measure for years prior to 2022 and we may determine a different financial performance measure to be the most important financial performance measure in future years.

Required Tabular Disclosure of Most Important Financial Performance Measures

The most important financial performance measures used by the company to link compensation actually paid to the company’s NEOs for the most recently completed fiscal year to the company’s performance are set forth below. For further information regarding these performance metrics and their function in our executive compensation program, please see the section titled “ Compensation Discussion and Analysis .”

• Net product sales

• Product candidate development

• Non-GAAP operating income

#### Mirum Pharmaceuticals2025 Proxy Statement49

#### TABLE OF CONTENTS

#### Executive Compensation
Required Disclosure of the Relationship Between CAP and Financial Performance Measures

As required by Item 402(v) of Regulation S-K, we are providing the following graphs to illustrate the relationship between the pay and performance figures that are included in the pay versus performance tabular disclosure above. In addition, the graph below under the heading “— Cumulative TSR of the Company and Cumulative TSR of the Peer Group ” further illustrates the relationship between Company total shareholder return and that of the NASDAQ Biotechnology Index. As noted above, CAP for purposes of the tabular disclosure and the following graphs was calculated in accordance with SEC rules and does not reflect the amount of compensation earned by or actually paid to our NEOs during the applicable years.

#### CAP and Net Loss
The chart below shows the relationship between the compensation actually paid to our PEO and the average compensation actually paid to our non-PEO NEO